Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Non-durable DME payments?

This article was originally published in The Gray Sheet

Executive Summary

10-year freeze in consumer price index for durable medical equipment, orthotics and prosthetics is folded into omnibus tax package (S 1054) approved by the Senate May 15. The provision, along with language addressing application of deductibles and coinsurance for clinical diagnostic lab tests and a reduction of the Average Wholesale Price for outpatient drugs, is intended to offset $25 bil. in Medicare payment increases to rural health providers. Included in the bill's reimbursement enhancements is a two-year extension of "reasonable cost payments" for certain diagnostic tests delivered in sole community hospitals. Finance Committee Chairman Charles Grassley (R-Iowa) introduced the amendment, which cleared the Senate earlier in the day in an 86-12 vote...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel